Erasca, Inc. (ERAS) Stock Analysis
Verdict: WATCH (do not buy)
Pre-revenue clinical biotech burn rate ($95.5M/yr) creates medium-term dilution risk, making upside contingent on early pipeline readouts.
Investment score: 41/100
Analysis as of
Is Erasca, Inc. stock worth reviewing? AI model thesis
The model score of 41/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 35/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Erasca, Inc. opportunities and risks
What speaks for ERAS
- Clinical pipeline focused on high-value RAS/MAPK cancer targets
What speaks against ERAS
- Severe cash runway constraint driving equity dilution
Frequently asked questions about Erasca, Inc. (ERAS)
Is ERAS stock a good investment?
The cached TradeMates AI model rates Erasca, Inc. as WATCH (do not buy) with an investment score of 41/100. The model score of 41/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Is ERAS stock a buy?
The TradeMates model verdict for ERAS is WATCH (do not buy) with an investment score of 41/100. Treat this as a model signal to review, not a personal buy recommendation.